CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Alex Aimetti, Ph.D., Senior Director, Medical Education and Scientific Support, will be giving a poster presentation at the 17th Annual Spinal Research Network Meeting to be held September 4-5, 2015 in London, UK. The abstract, titled “Benefits of Surgical Implantation of an Investigational Biodegradable Neuro-Spinal Scaffold in Various Animal Models of Acute Spinal Cord Contusion Injury: Clinical Translation,” is co-authored by Dr. Aimetti, James Guest, M.D., Nicholas Theodore, M.D., Domagoj Coric, M.D., Lorianne Masuoka, M.D., Simon Moore, Ph.D., Richard Layer, Ph.D., and Thomas Ulich, M.D.
“This presentation is the product of experts in both research and clinical arenas and serves as a great opportunity for us to raise awareness of our novel approach with leaders in the spinal cord injury community”
“This presentation is the product of experts in both research and clinical arenas and serves as a great opportunity for us to raise awareness of our novel approach with leaders in the spinal cord injury community,” InVivo’s CEO and Chairman Mark Perrin said.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
